Unmet Needs and Challenges in Lymphoma

EP: 1.The Evolving Treatment Landscape of Leukemia

EP: 2.Recent Data from ASH 2023 in Leukemia

EP: 3.Long-Term Results of the OPTIC Trial in CML

EP: 4.Subgroup Analysis of the Phase 3 PhALLCON Study of Ponatinib in Ph+ ALL

EP: 5.Key Takeaways from Recent Updates in Leukemia

EP: 6.Challenges in Managing Adverse Events and Unmet Needs in Leukemia

EP: 7.The Evolving Lymphoma Treatment Landscape

EP: 8.Subcutaneous Mosunetuzumab in Follicular Lymphoma

EP: 9.Recent Data on Axi-Cel in Lymphoma

EP: 10.Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

EP: 11.CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

Now Viewing

EP: 12.Unmet Needs and Challenges in Lymphoma

Transcript:

Lori A. Leslie, MD: Though we have made dramatic improvements in the treatment options available for patients with various lymphoma subtypes over the last few years, we still have much work ahead. I think patient selection is very important. We’re working on how to optimally risk stratify patients on an individual level to determine the best treatment for the specific factors driving each case. We also must identify patients having suboptimal responses to therapy earlier to be able to shift gears, perhaps via consolidative treatments after frontline chemoimmunotherapy or post-CAR T-cell therapy for those not achieving deep molecular remissions. Doing so can facilitate the continued evolution of lymphoma care toward providing curative intent options for all patients.

Thank you for joining me for this informative discussion. We hope you found this OncLive Peer Exchange discussion useful and valuable for treating your patients.

Transcript edited for clarity.